[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
September 15, 1951


Author Affiliations

New York

From the Department of Medicine of Cornell University Medical College and New York Hospital.

JAMA. 1951;147(3):227-229. doi:10.1001/jama.1951.03670200019006

Recent investigations of the value of anticoagulants in myocardial infarction have indicated the need for a critical analysis of the blood-clotting mechanism in this disease.1 Observations have been reported2 which suggest that there is an increased tendency toward a coagulation associated with coronary thrombosis. Certain studies have yielded evidence that "hyperprothrombinemia" (in reality a summation of factors producing a shortening of the prothrombin time) is one of the factors responsible for the increased clotting tendency.3 The importance of careful inquiry into whether such a state actually exists in patients with coronary thrombosis becomes obvious when the use of the anticoagulant drugs for both treatment and prophylaxis is being considered. Opportunity to observe daily prothrombin times in patients in whom coronary occlusion with myocardial infarction developed was afforded us during studies of the use of bishydroxycoumarin (dicumarol®) in this syndrome. The data obtained from observations of a group